Statins and safety: applying the results of randomized trials to clinical practice (Q35217933)

7 August 2017

1 reference

title

Statins and safety: applying the results of randomized trials to clinical practice (English)

1 reference

7 August 2017

David Waters

1

1 reference

PubMed ID

12972108

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

6

1 reference

7 August 2017

692-695

1 reference

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Risk factor thresholds: their existence under scrutiny

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Report of the Conference on Low Blood Cholesterol: Mortality Associations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Risk of cataract in patients treated with statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Cerivastatin and reports of fatal rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statin-associated myopathy with normal creatine kinase levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Carcinogenicity of lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Do statins cause cancer? A meta-analysis of large randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statin use and the risk of breast and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statin use, hyperlipidaemia, and the risk of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statin use and the risk of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Statins can inhibit proliferation of human breast cancer cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Long-term persistence in use of statin therapy in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900825-7

10.1016/S0002-9149(03)00825-7

7 January 2021

Identifiers

DOI

1 reference

release_23jmtke6bngyhjel7zie3lv26y

7 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/23jmtke6bngyhjel7zie3lv26y

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12972108

1 reference

PubMed ID

12972108